Abstract
Of the commonly recognized structural elements within nucleic acids, bulges are among the least developed as targets for small molecules. Bulges in DNA and RNA have been linked to biomolecular processes involved in numerous diseases, thus probes with affinity for these targets would be of considerable utility to chemical biologists and medicinal chemists. Despite such opportunity, there is a dearth of small molecules available with affinity for bulges, which has hampered exploitation of these key targets. We have used guided chemical synthesis to prepare small molecules capable of binding to DNA and RNA bulges. Our design is based on a template which mimics a metabolite of the enediyne neocarzinostatin. The key spirocylic building block was formed through an intramolecular aldol process and the parent template shows pronounced affinity for 2 base bulges. Functionalization with specific aminosugar moieties confers nanomolar binding affinity for selected bulged DNA targets, and installation of reactive functional groups allows covalent modification of bulges. These rationally designed agents can now be used to study the stereochemistry and architecture of bulge-drug complexes and investigate the molecular biology of bulge induced processes. Members of this class have been shown to induce slipped synthesis of DNA, suggesting the agents, in addition to recognizing and binding to pre-formed bulges, can also induce bulge formation on demand.
Current Topics in Medicinal Chemistry
Title: Congeners of the Enediyne Neocarzinostatin Chromophore: Designed Agents for bulged Nucleic Acid Targets
Volume: 8 Issue: 6
Author(s): Graham B. Jones, Yiqing Lin, Dong Ma, Ziwei Xiao, Geum-Sook Hwang, Lizzy Kappen and Irving H. Goldberg
Affiliation:
Abstract: Of the commonly recognized structural elements within nucleic acids, bulges are among the least developed as targets for small molecules. Bulges in DNA and RNA have been linked to biomolecular processes involved in numerous diseases, thus probes with affinity for these targets would be of considerable utility to chemical biologists and medicinal chemists. Despite such opportunity, there is a dearth of small molecules available with affinity for bulges, which has hampered exploitation of these key targets. We have used guided chemical synthesis to prepare small molecules capable of binding to DNA and RNA bulges. Our design is based on a template which mimics a metabolite of the enediyne neocarzinostatin. The key spirocylic building block was formed through an intramolecular aldol process and the parent template shows pronounced affinity for 2 base bulges. Functionalization with specific aminosugar moieties confers nanomolar binding affinity for selected bulged DNA targets, and installation of reactive functional groups allows covalent modification of bulges. These rationally designed agents can now be used to study the stereochemistry and architecture of bulge-drug complexes and investigate the molecular biology of bulge induced processes. Members of this class have been shown to induce slipped synthesis of DNA, suggesting the agents, in addition to recognizing and binding to pre-formed bulges, can also induce bulge formation on demand.
Export Options
About this article
Cite this article as:
Jones B. Graham, Lin Yiqing, Ma Dong, Xiao Ziwei, Hwang Geum-Sook, Kappen Lizzy and Goldberg H. Irving, Congeners of the Enediyne Neocarzinostatin Chromophore: Designed Agents for bulged Nucleic Acid Targets, Current Topics in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/156802608783955692
DOI https://dx.doi.org/10.2174/156802608783955692 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Current Computational Approaches Towards the Rational Design of New Insecticidal Agents
Current Computer-Aided Drug Design Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Editorial [Hot Topic: Biomarkers of Chemotherapeutics Efficacy and Toxicity in Colorectal Cancer (Guest Editor: Amalia Azzariti)]
Current Drug Metabolism Gastric Cancer: Nanoparticles as Tools to Improve Treatment Efficacy
Current Pharmaceutical Design The History, Mechanism and Clinical Use of Oral 5-Fluorouracil Derivative Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice
Protein & Peptide Letters Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
Current Drug Targets Cross-Talk between Tumor Cells and the Microenvironment at the Metastatic Niche
Current Pharmaceutical Biotechnology 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences